Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    BeiGene protects the world with affordable Chinese therapies

    By Liu Zhihua | China Daily | Updated: 2019-12-30 10:38
    Share
    Share - WeChat
    Wu Xiaobin, president of BeiGene. [Photo provided to China Daily]

    The two drugs were approved only six months later as two foreign anti-PD-1 treatments entered the China market, and followed shortly by a third domestic PD-1 treatment early this year.

    BeiGene's anti-PD-1 treatment also obtained approval from the Chinese drug regulatory authorities on Saturday.

    The company has been also implementing about 20 clinical trial programs globally on Brukinsa's efficacy on other types of blood or lymph tumors, with high hope to get more market approvals in the near future.

    The company, which has nearly 10 new drug candidates in pipeline, is a partner in a global strategic oncology collaboration with Amgen, a California-based biopharmaceutical company that is a global leader in this niche.

    Chinese biotech firms are increasingly offering China-developed high-quality treatments to Chinese patients, which will help challenge the expensive prices of imported drugs, Wu said.

    With innovative drugs such as anti-PD-1 and Brukinsa, Chinese drug companies also have the ability to offer treatment options for patients abroad, especially those in the Belt and Road economies, he said.

    Wu joined the Beijing-headquartered company in 2018 from Pfizer China, which he headed since 2009.

    His jump to the Chinese biotech startup founded in 2010 surprised many as he had more than 26 years of rich experience in the pharmaceutical industry, including 17 years leading China operations of big-name multinational pharmaceuticals such as Wyeth and Bayer.

    He returned to Beijing in 1996 to co-build Bayer's China branch as marketing head. Prior, he was in Germany where he received a master's degree in molecular biology and a PhD in biochemistry and pharmacology from the University of Konstanz. He started his career at Bayer's sales and marketing in 1992.

    In 2004, he rose to general manager of Wyeth China. In 2009, as Pfizer acquired Wyeth, he was named head of the combined group.

    He also served as vice chairman of the R&D-based Pharmaceutical Association Committee of the China Association of Enterprises with Foreign Investment since 2008.

    Under his belt are numerous industry awards, including the "Person of the Year" in Healthy China Awards 2017, "2017 Top 10 Most Influential Persons in the Chinese Healthcare Industry" and the "2017 Social Responsibility Eminent Person Award".

    |<< Previous 1 2   
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    无码国产午夜福利片在线观看| 亚洲中文久久精品无码| 日韩中文字幕欧美另类视频| 黄A无码片内射无码视频| 亚洲日本中文字幕天天更新| 在线看福利中文影院| 人妻无码第一区二区三区| 日韩人妻无码一区二区三区久久99 | 忘忧草在线社区WWW中国中文 | HEYZO无码综合国产精品| 亚洲欧洲自拍拍偷午夜色无码| а√天堂中文官网8| 久久精品中文无码资源站| 本免费AV无码专区一区| 无码日韩精品一区二区免费暖暖 | 大地资源中文在线观看免费版| 成人无码视频97免费| 少妇无码一区二区三区免费| 在线播放无码高潮的视频| 中文字幕丰满乱子无码视频| 国产在线精品一区二区中文| 无码内射中文字幕岛国片| 中文字幕亚洲精品无码 | 精品久久久无码人妻中文字幕豆芽| 无码人妻少妇伦在线电影| 久久精品?ⅴ无码中文字幕| 精品久久久久久无码人妻蜜桃| 国产三级无码内射在线看| 国产AV无码专区亚洲Av| 丰满熟妇人妻Av无码区| 国产精品无码A∨精品影院| 国产拍拍拍无码视频免费| 国产乱子伦精品无码码专区| 国产真人无码作爱视频免费| 久久久久久久久无码精品亚洲日韩 | 亚洲中文字幕无码爆乳av中文| 西西4444www大胆无码| 中文字幕在线观看有码| 中文字幕亚洲欧美专区| 国产日韩精品中文字无码| 一区二区三区在线观看中文字幕 |